Blog Entry
Pharmaceutical Tariffs: Potential Impacts And The Need For Vulnerability Assessments
Thomas Roades, Stephen Colvill, Mark McClellan
Health Affairs, 2025
Read MoreWhite Paper
Supporting Evidence Generation of Indirect Benefits and Risks for Medical Products Used for Infectious Diseases
Brian Canter, Nancy Allen LaPointe, Sabine Sussman, Mark McClellan
2025
Read MoreWhite Paper
Integrating Indirect Health Benefits into Biomedical Policy: Key Reforms for Federal Agencies to Reduce Disease Transmission
Sabine Sussman, Brian Canter, Mark McClellan
2025
Read MoreComment Letter
Comment Letter on CMS Proposed Guidance Document: Study Protocols That Use Real-world Data
Hannah Graunke, Beena Bhuiyan Khan
2025
Read More